Q1 Surge, Future Uncertain: Novo Nordisk’s Obesity Drug Dilemma

Unknown Apr 02, 2026 1,300 Views

Novo Nordisk, the world's largest obesity and diabetes medicine maker, reported a better-than-expected Q1 profit but dampened investor optimism by lowering its 2025 sales forecast, citing weaker trends for its best-selling medicines and increasing competition. Key Highlights:...